Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Telix Pharmaceuticals ( (AU:TLX) ) is now available.
Telix Pharmaceuticals has applied to the ASX for quotation of 50,782 new fully paid ordinary shares issued under its employee share and stock purchase plans. The additional securities, dated March 12, 2026, modestly expand the company’s share capital while reinforcing employee ownership and aligning staff incentives with long-term shareholder value.
The issuance reflects ongoing use of equity-based compensation to support Telix’s talent retention and engagement strategy in a competitive biotech sector. For investors, the move represents a small level of dilution but signals continued growth and maturation of the company’s global operations and workforce participation in its equity programs.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$31.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on developing and commercialising radiopharmaceuticals for cancer diagnosis and treatment. Listed on the ASX under the ticker TLX, the company targets global oncology markets with a pipeline of imaging and therapeutic products designed to improve precision medicine in oncology.
Average Trading Volume: 2,907,027
Technical Sentiment Signal: Sell
Current Market Cap: A$3.73B
Find detailed analytics on TLX stock on TipRanks’ Stock Analysis page.